[Extrapyramidal symptoms during the use of neuroleptics].
D002090:Butyrophenones / Q000009:adverse effects; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D005116:Extrapyramidal Tracts / Q000187:drug effects* / Q000503:physiopathology*; D006801:Humans; D008620:Meprobamate; D009069:Movement Disorders / Q000139:chemically induced*; D010276:Parasympatholytics / Q000627:therapeutic use; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D010640:Phenothiazines / Q000009:adverse effects; D011600:Psychopharmacology; D012110:Reserpine / Q000009:adverse effects
D002090:Butyrophenones; D000697:Central Nervous System Stimulants; D010276:Parasympatholytics; D010640:Phenothiazines; D012110:Reserpine; D008620:Meprobamate
Extrapyramidale Symptome bei der Anwendung von Neuroleptica.